drugset

drugset / Trial / NCT05010434

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

NCT05010434 ↗

Phase 2 Unknown 46 enrolled Sun Yat-sen University Innovent Biologics (Suzhou) Co. Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced hepatocellular carcinoma.

Timeline

Start: 2021-08-16
Primary completion: 2023-09
Completion: 2023-09

Publications

Zhu M, Liu Z, Chen S, Luo Z, Tu J, Qiao L, Wu J, Fan W, Peng Z. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study. Hepatology. 2024 Oct 1;80(4):807-815. doi: 10.1097/HEP.0000000000000776. Epub 2024 Feb 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	—
Subject	Sintilimab	Monoclonal antibody	200 mg	Intravenous

Indications